Clinical data | |
---|---|
Trade names | Tryvio |
Other names | ACT-132577 |
Routes of administration | By mouth |
Drug class | Antihypertensive |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C16H14Br2N6O4S |
Molar mass | 546.19 g·mol−1 |
3D model (JSmol) | |
| |
|
Aprocitentan, sold under the brand name Tryvio, is a medication used for the treatment of hypertension (high blood pressure).[1] It is an endothelin receptor antagonist active at both endothelin A and endothelin B receptors.[2] It is developed for resistant hypertension by Idorsia, which sold it to Janssen but purchased the rights back in 2023 for $343 million.[3]
Aprocitentan is an active metabolite of macitentan.[4]
Aprocitentan was approved for medical use in the United States in March 2024.[1]
Medical uses[edit]
Aprocitentan is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other drugs.[1]
References[edit]
- ^ a b c d "Tryvio- aprocitentan tablet, film coated". DailyMed. 29 March 2024. Retrieved 25 April 2024.
- ^ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; et al. (2022). "Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs. 22 (3): 271–285. doi:10.1007/s40256-021-00510-9. PMC 8651502. PMID 34878631.
- ^ Deswal, Phalguni (6 September 2023). "Idorsia reacquires aprocitentan rights from Janssen for $343m". Pharmaceutical Technology. Archived from the original on 8 November 2023. Retrieved 8 November 2023.
- ^ CID 25099191 from PubChem